Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2013

View Archived Issues

Researchers at AbbVie synthesize new compounds for RSV infection

Tris Pharma and FSC Laboratories sign commercialization agreement for Karbinal ER

Comfrey root extract with methyl nicotinate effective for low back pain

Crinetics Pharmaceuticals receives grant to develop drugs for pituitary tumors

ThromboGenics and Bicycle Therapeutics to collaborate on bicyclic peptide inhibitors

Novel genetic locus associated with a childhood gastrointestinal disease identified

Proof-of-concept for gene therapy-mediated retinal rescue using a novel transgenic mouse model

Gene-centric association study of complications associated with sickle cell disease

XBiotech begins preclinical study of antibody therapy for MRSA

First milestone reached within Karo Bio and Pfizer's RORgamma collaboration

KemPharm expands pain therapy pipeline with KP-606

FDA accepts complete response submission to Aveed NDA

Bayer HealthCare applies for approval of regorafenib for GIST in Europe

Tablet formulation of Boldocynara shows efficacy in patients with functional digestive disorders

RQx Pharmaceuticals patents new signal peptidase inhibitors

New York University and USC patent novel agents for cancer and other disorders

New kinase inhibitors synthesized at Merck KGaA

Extract from S. scardica shows promise for Alzheimer's disease treatment

Otsuka Pharmaceutical to acquire Astex Pharmaceuticals

Viamet begins phase II studies of antifungal VT-1161

Medivir and Daewoong discontinue development of hepatitis B compound

Novel vaccines for tuberculosis disclosed

Almac Discovery and Queen's University Belfast form new partnership

Plasma uridine as a biomarker of ornithine transcarbamylase deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.